Literature DB >> 28443960

Positioning about the Flexibility of Fasting for Lipid Profiling.

Marileia Scartezini1, Carlos Eduardo Dos Santos Ferreira2, Maria Cristina Oliveira Izar3, Marcello Bertoluci4, Sergio Vencio5, Gustavo Aguiar Campana2, Nairo Massakazu Sumita2, Luiz Fernando Barcelos1, André A Faludi3, Raul D Santos3, Marcus Vinícius Bolívar Malachias3, Jerolino Lopes Aquino1, César Alex de Oliveira Galoro2, Cleide Sabino4, Maria Helane Costa Gurgel4, Luiz Alberto Andreotti Turatti5, Alexandre Hohl4, Tania Leme da Rocha Martinez3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28443960      PMCID: PMC5389867          DOI: 10.5935/abc.20170039

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


× No keyword cloud information.

Justifications

The review of the need of fasting for lipid profile analysis (total cholesterol, LDL-C, HDL-C, non-HDL-C, and triglycerides [TG]) is based on the following grounds: Since the postprandial state predominates during most of the day, the patient is more exposed to the lipid levels in this condition when compared with the fasting state. Therefore, the postprandial state may represent more effectively the potential impact of the lipid levels on an individual's cardiovascular risk. Measurements in the postprandial state are more practical and provide the patient a greater access to the laboratory, decreasing the number of missed working days and medical appointments due to missed tests, allowing a better assessment of the individual's cardiovascular risk. Blood collection in the postprandial state is safer in several circumstances and may help prevent hypoglycemia secondary to the use of insulin in patients with diabetes mellitus, or due to prolonged fasting in pregnant women, children, and elderly individuals, minimizing complications and increasing the adherence to the tests and the attendance to medical appointments. There are no significant differences in measurements of total cholesterol, HDL-C, non-HDL-C, and LDL-C performed in the postprandial or fasting state. Levels of TG increase in the fed state, but such increase has little relevance as far as a regular meal without fat overload is considered, with the possibility of adjustment in the reference values.[1-7] With a flexibility for lipid profiling, there is a greater amplitude of schedules, thereby reducing congestion in the laboratories, especially early in the morning, bringing more comfort to the patient. With the technological advances in diagnostic methods, the main assays available have mitigated the interference caused by increased sample turbidity due to high TG concentrations. However, there are potential limitations, especially related to the calculation of LDL-C, in which performance studies of different methodologies have shown a need for a revision of the practical use of the adopted formulas.

Clinical and Laboratory Aspects in the Flexibility of Fasting for Lipid Profile Analysis

In easing the requirement for fasting in the collection of samples for lipid profile assessment, some clinical and laboratory recommendations become important.

Recommendations for the care of the patient in the laboratory

Nonfasting sample collection for lipid profiling: may be done by the laboratory with the presence of the information about fasting at the time of sample collection in the laboratory report. A medical request without a definition of the fasting duration and without other tests known to require fasting: it is recommended to include in the laboratory report the fasting duration informed at the time of the sample collection. Presence in the same request of other tests that require fasting: the laboratory may define that the lipid profile should be collected with a 12-hour fasting when other laboratory tests, ordered on the same request, also require this period of fasting. The laboratory is recommended to specify whether or not fasting is required for each exam: no fasting, 12-hour fasting, or according to the definition set by the laboratory. When an indication of a specific fasting duration is present: if the request by the physician has a specific fasting duration, the laboratory should follow such recommendation. The calculation of hours of fasting by the "SIL" (Laboratory Information System, Sistema de Informação Laboratorial) may be used, based on the information of the time elapsed since the last meal. When the TG levels in the postprandial state are > 440 mg/dL, or in the presence of special situations such as the recovery from pancreatitis secondary to hypertriglyceridemia, or at the beginning of a treatment with drugs that cause severe hypertriglyceridemia, the prescribing physician is recommended to request a new TG evaluation with a 12-hour fasting and this will be considered as a new TG test by the laboratory.[1] When the second sample collection for TG measurement occurs: the use of the same code or another specific code for the TG measurement without fasting and after a 12-hour fast will be at the discretion of each laboratory, depending on its system and strategy.

Template recommendations for the laboratory's report

The report is a responsibility of the laboratory and its technical manager. With the purposes of alignment and harmonization among the institutions, it is recommended the adoption of the following information in the report: The reference values and therapeutic target for the lipid profile (adults aged > 20 years) according to the cardiovascular risk assessment estimated by the prescribing physician are described in Table 1.[1,8,9]
Table 1

Reference values and therapeutic targets for adults > 20 years according to the patient’s cardiovascular risk assessed by the physician requesting the lipid profile

LipidsWith fasting (mg/dL)Without fasting (mg/dL)Referential category
Total cholesterol*< 190< 190Desirable
HDL-C> 40> 40Desirable
Triglycerides**< 150< 175Desirable
   Risk category
LDL-C< 130 < 100 < 70 < 50< 130 < 100 < 70 < 50Low Intermediary High Very high
Non-HDL-C< 160 < 130 < 100 < 80< 160 < 130 < 100 < 80Low Intermediary High Very high

Total cholesterol > 310 mg/dL: consider the likelihood of familial hypercholesterolemia;

When the triglyceride levels are above 440 mg/dL (without fasting), the prescribing physician must request a new triglycerides measurement after 12-hour fasting and the laboratory should consider this as a new triglycerides test.

Reference values and therapeutic targets for adults > 20 years according to the patient’s cardiovascular risk assessed by the physician requesting the lipid profile Total cholesterol > 310 mg/dL: consider the likelihood of familial hypercholesterolemia; When the triglyceride levels are above 440 mg/dL (without fasting), the prescribing physician must request a new triglycerides measurement after 12-hour fasting and the laboratory should consider this as a new triglycerides test. Insertion of a note in the report referencing that the lipid profile results should be interpreted according to the clinical assessment and evolution of the patient. The following sentence is recommended: "The clinical interpretation of the results should take into account the reason for indication of the test, the metabolic state of the patient, and the stratification of risk for establishment of the therapeutic goals." The target reference values of the lipid profile for children and adolescents are shown in Table 2.[10,11]
Table 2

Reference values of lipid profile for children and adolescents

LipidsWith fasting (mg/dL)Without fasting (mg/dL)
Total cholesterol*< 170< 170
HDL-C> 45> 45
Triglycerides (0-9 years) **< 75< 85
Triglycerides (10-19 years) **< 90< 100
LDL-C< 110< 110

Total cholesterol > 230 mg/dL: consider the likelihood of familial hypercholesterolemia;

When the triglycerides levels are above 440 mg/dL (without fasting), the prescribing physician must request a new triglycerides measurement after 12-hour fasting and the laboratory should consider this as a new triglycerides test.

Reference values of lipid profile for children and adolescents Total cholesterol > 230 mg/dL: consider the likelihood of familial hypercholesterolemia; When the triglycerides levels are above 440 mg/dL (without fasting), the prescribing physician must request a new triglycerides measurement after 12-hour fasting and the laboratory should consider this as a new triglycerides test. Patients with diabetes and no risk factors or evidence of subclinical atherosclerosis should maintain LDL-C levels below 100 mg/dL. Patients with risk factors or subclinical atherosclerotic disease should maintain LDL-C levels below 70 mg/dL. Patients with a history of acute myocardial infarction; stroke; coronary, carotid or peripheral revascularization; or history of amputation should maintain the LDL-C levels below 50 mg/dL. The inclusion of a specific note about the screening of familial hypercholesterolemia (FH) is left at the discretion of the laboratory. The following sentence is recommended: "Values of total cholesterol > 310 mg/dL in adults or ≥ 230 mg/dL in children and adolescents may be indicative of familial hypercholesterolemia, if secondary dyslipidemias are excluded."[14]

Recommendations about formulas and direct LDL-C measurement

The assessment of LDL-C can be performed by direct measurement or estimated by calculation based on Friedewald's or Martin's formula.[13] The following recommendations are suggested to the laboratories: Observe the limitations of nonfasting and TG values > 400 mg/dL when Friedewald's formula[15] is used to estimate LDL-C; in these cases, Martin's formula[16] or direct measurement should be used. When collecting postprandial samples, the LDL-C measurement can be performed by direct measurement or calculated using Martin's formula.[16] Include non-HDL-C in the calculation along with other results of the lipid profile in adults, even without fasting, since the TG levels do not interfere in such calculation. Reporting or not of the VLDL-C calculation may be done at the discretion of the laboratory. The main purpose of this document is to standardize the clinical and laboratory actions in regards to the flexibility of fasting in the lipid profile analysis across the national territory, contributing to offer security to the decision-making process by physicians and laboratories, grounded by scientific evidence.
  16 in total

1.  [V Brazilian Guidelines on Dyslipidemias and Prevention of Atherosclerosis].

Authors:  H T Xavier; M C Izar; J R Faria Neto; M H Assad; V Z Rocha; A C Sposito; F A Fonseca; J E dos Santos; R D Santos; M C Bertolami; A A Faludi; T L R Martinez; J Diament; A Guimarães; N A Forti; E Moriguchi; A C P Chagas; O R Coelho; J A F Ramires
Journal:  Arq Bras Cardiol       Date:  2013-10       Impact factor: 2.000

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Fasting might not be necessary before lipid screening: a nationally representative cross-sectional study.

Authors:  Michael J Steiner; Asheley Cockrell Skinner; Eliana M Perrin
Journal:  Pediatrics       Date:  2011-08-01       Impact factor: 7.124

Review 4.  Fasting or Nonfasting Lipid Measurements: It Depends on the Question.

Authors:  Steven L Driver; Seth S Martin; Ty J Gluckman; Julie M Clary; Roger S Blumenthal; Neil J Stone
Journal:  J Am Coll Cardiol       Date:  2016-03-15       Impact factor: 24.094

5.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

6.  Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III).

Authors:  Bethany Doran; Yu Guo; Jinfeng Xu; Howard Weintraub; Samia Mora; David J Maron; Sripal Bangalore
Journal:  Circulation       Date:  2014-07-11       Impact factor: 29.690

7.  Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?

Authors:  Nader Rifai; Ian S Young; Børge G Nordestgaard; Anthony S Wierzbicki; Hubert Vesper; Samia Mora; Neil J Stone; Jacques Genest; Greg Miller
Journal:  Clin Chem       Date:  2016-01-19       Impact factor: 8.327

8.  Postprandial changes of lipoprotein profile: effect of abdominal obesity.

Authors:  Peter Sabaka; Peter Kruzliak; Ludovit Gaspar; Martin Caprnda; Matej Bendzala; David Balaz; Stanislav Oravec; Andrej Dukat
Journal:  Lipids Health Dis       Date:  2013-12-08       Impact factor: 3.876

9.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983

10.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Authors:  P M Kearney; L Blackwell; R Collins; A Keech; J Simes; R Peto; J Armitage; C Baigent
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321

View more
  7 in total

1.  Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019.

Authors:  Dalton Bertolim Précoma; Gláucia Maria Moraes de Oliveira; Antonio Felipe Simão; Oscar Pereira Dutra; Otávio Rizzi Coelho; Maria Cristina de Oliveira Izar; Rui Manuel Dos Santos Póvoa; Isabela de Carlos Back Giuliano; Aristóteles Comte de Alencar Filho; Carlos Alberto Machado; Carlos Scherr; Francisco Antonio Helfenstein Fonseca; Raul Dias Dos Santos Filho; Tales de Carvalho; Álvaro Avezum; Roberto Esporcatte; Bruno Ramos Nascimento; David de Pádua Brasil; Gabriel Porto Soares; Paolo Blanco Villela; Roberto Muniz Ferreira; Wolney de Andrade Martins; Andrei C Sposito; Bruno Halpern; José Francisco Kerr Saraiva; Luiz Sergio Fernandes Carvalho; Marcos Antônio Tambascia; Otávio Rizzi Coelho-Filho; Adriana Bertolami; Harry Correa Filho; Hermes Toros Xavier; José Rocha Faria-Neto; Marcelo Chiara Bertolami; Viviane Zorzanelli Rocha Giraldez; Andrea Araújo Brandão; Audes Diógenes de Magalhães Feitosa; Celso Amodeo; Dilma do Socorro Moraes de Souza; Eduardo Costa Duarte Barbosa; Marcus Vinícius Bolívar Malachias; Weimar Kunz Sebba Barroso de Souza; Fernando Augusto Alves da Costa; Ivan Romero Rivera; Lucia Campos Pellanda; Maria Alayde Mendonça da Silva; Aloyzio Cechella Achutti; André Ribeiro Langowiski; Carla Janice Baister Lantieri; Jaqueline Ribeiro Scholz; Silvia Maria Cury Ismael; José Carlos Aidar Ayoub; Luiz César Nazário Scala; Mario Fritsch Neves; Paulo Cesar Brandão Veiga Jardim; Sandra Cristina Pereira Costa Fuchs; Thiago de Souza Veiga Jardim; Emilio Hideyuki Moriguchi; Jamil Cherem Schneider; Marcelo Heitor Vieira Assad; Sergio Emanuel Kaiser; Ana Maria Lottenberg; Carlos Daniel Magnoni; Marcio Hiroshi Miname; Roberta Soares Lara; Artur Haddad Herdy; Cláudio Gil Soares de Araújo; Mauricio Milani; Miguel Morita Fernandes da Silva; Ricardo Stein; Fernando Antonio Lucchese; Fernando Nobre; Hermilo Borba Griz; Lucélia Batista Neves Cunha Magalhães; Mario Henrique Elesbão de Borba; Mauro Ricardo Nunes Pontes; Ricardo Mourilhe-Rocha
Journal:  Arq Bras Cardiol       Date:  2019-11-04       Impact factor: 2.000

Review 2.  The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.

Authors:  Pratik B Sandesara; Salim S Virani; Sergio Fazio; Michael D Shapiro
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  Non-fasting lipid profile for cardiovascular risk assessments using China ASCVD risk estimator and Europe SCORE risk charts in Chinese participants.

Authors:  Shi-Lan Zhang; Xiao Du; Jin Xu; Qun-Yan Xiang; Ling Liu
Journal:  Cardiovasc Diagn Ther       Date:  2021-08

4.  Prevalence of IGFBP3, NOS3 and TCF7L2 polymorphisms and their association with hypertension: a population-based study with Brazilian women of African descent.

Authors:  Abel Barbosa Lira Neto; Nancy Borges Rodrigues Vasconcelos; Tamara Rodrigues Dos Santos; Luisa Elvira Cavazzani Duarte; Monica Lopes Assunção; Carolinne de Sales-Marques; Haroldo da Silva Ferreira
Journal:  BMC Res Notes       Date:  2021-05-17

5.  Circulating Interleukin-6 (but Not Other Immune Mediators) Associates with Criteria for Fried's Frailty among Very Old Adults.

Authors:  Gilberto Santos Morais Junior; Diego Ignacio Valenzuela Perez; Audrey Cecília Tonet-Furioso; Lucy Gomes; Karla Helena Coelho Vilaça; Vicente Paulo Alves; Clayton Franco Moraes; Otávio Toledo Nóbrega
Journal:  J Aging Res       Date:  2020-11-04

6.  The Role of Fasting LDL-C Levels in Their Non-fasting Reduction in Patients With Coronary Heart Disease.

Authors:  Qiuzhen Lin; Yan Fu; XueYan Zang; Qiming Liu; Ling Liu
Journal:  Front Cardiovasc Med       Date:  2021-06-16

7.  Counterpoint: Flexibilization of Fasting for Laboratory Determination of the Lipid Profile in Brazil: Science or Convenience?

Authors:  Maria Cristina de Oliveira Izar
Journal:  Arq Bras Cardiol       Date:  2018-11       Impact factor: 2.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.